Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › EVMN

Pivotal bioVenture Partners Investment Advisor LLC position in EVMN

EVOMMUNE INC · Health Care

Pivotal bioVenture Partners Investment Advisor LLC reported holding 1,926,943 shares of EVMN (EVOMMUNE INC) in its Q3 2026 13F filing — a position valued at US$15.9M, representing 6.49% of its reported portfolio and ranking #5 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC has disclosed EVMN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)1.93M sh
Reported value held$15.92M
Portfolio Weight6.49%
First reportedQ4 2025
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Pivotal bioVenture Partners Investment Advisor LLC's EVMN position evolved

Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in EVMN in Q4 2025 at 1,926,943 shares (US$33.0M). The position peaked in Q1 2026 at 1,926,943 shares, worth US$44.3M. Across 4 filings, Pivotal bioVenture Partners Investment Advisor LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,926,943 shares valued at US$15.9M.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.93M $32.99M New
Q1 2026 1.93M $44.30M Hold
Q2 2026 1.93M $25.61M Hold
Q3 2026 1.93M $15.92M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EVMN and 13F data

EVMN (EVOMMUNE INC) is a Health Care company. 105 other funds we track also report a position in EVMN — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$46.4M), EQT Fund Management S.a r.l. (US$43.7M), SymBiosis Capital Partners, LLC (US$29.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EVMN

All EVMN fund holders →

FAQ

How long has Pivotal bioVenture Partners Investment Advisor LLC held EVMN?

Pivotal bioVenture Partners Investment Advisor LLC has disclosed EVMN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Pivotal bioVenture Partners Investment Advisor LLC's current position in EVMN?

As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 1.93M shares of EVMN (EVOMMUNE INC), valued at $15.92M, representing 6.49% of its reported portfolio and ranking #5.

Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling EVMN?

In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC held unchanged its position in EVMN. The position peaked in Q1 2026 at 1.93M shares.

Which other funds hold EVMN?

Other major institutional holders of EVMN include RA CAPITAL MANAGEMENT, L.P., EQT Fund Management S.a r.l., SymBiosis Capital Partners, LLC, among 105 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.